Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
in Bavaria, the "Bavarian Patriotic Party", with a particularistic-conservative bent, since 1887 called the "Bavarian Centre". The Catholic People's Party was formed in the Grand Duchy of Baden in 1869, and merged into the Centre Party in 1888.
== History == Flavoproteins were first discovered in 1879 by separating components of cow's milk. They were initially called lactochrome due to their milky origin and yellow pigment. It took 50 years for the scientific community to make any substantial progress in identifying the molecules responsible for the yellow pigment. The 1930s launched the field of coenzyme research with the publication of many flavin and nicotinamide derivative structures and their obligate roles in redox catalysis. German scientists Otto Warburg and Walter Christian discovered a yeast derived yellow protein required for cellular respiration in 1932. Their colleague Hugo Theorell separated this yellow enzyme into apoenzyme and yellow pigment, and showed that neither the enzyme nor the pigment was capable of oxidizing NADH on their own, but mixing them together would restore activity. Theorell confirmed the pigment to be riboflavin's phosphate ester, flavin mononucleotide (FMN) in 1937, which was the first direct evidence for enzyme cofactors. Warburg and Christian then found FAD to be a cofactor of D-amino acid oxidase through similar experiments in 1938. Warburg's work with linking nicotinamide to hydride transfers and the discovery of flavins paved the way for many scientists in the 40s and 50s to discover copious amounts of redox biochemistry and link them together in pathways such as the citric acid cycle and ATP synthesis.
=== Alternative pre-mRNA splicing generates multiple proteins from a single gene === The great majority of protein-coding genes encoded within the nucleus of metazoan cells contain multiple introns. In many cases, these introns were shown to be processed in more than one pattern, thus generating a family of related mRNAs that differ, for example, by the inclusion or exclusion of particular exons. The result of alternative splicing is that a single gene can encode a number of different protein isoforms that can exhibit a variety of (usually related) biological functions. Indeed, most of the proteins encoded by the human genome are generated by alternative splicing.
Sources: en.wikipedia.org
=== Behavioral immunity === When the mealworms feed on infected rodent feces, they may consume the eggs of the parasitic tapeworm Hymenolepis diminuta. Infected male beetles pay a higher reproductive cost than the female beetles. T. molitor displays behavioral immunity when exposed to H. diminuta, shown by how the infected males develop an avoidance behavior for feces that harbor the tapeworm, which decreases their probability of coming into contact with the tapeworm in the future. The female mealworm beetles develop a qualitative resistance through mate choice, as they are able to evaluate male immunocompetence through pheromone signaling, allowing them to choose the more immunologically fit males as mates. This also reduces the probability of the females being infected by their mates, and may cause them to pass on an enhanced level of immunocompetence to their offspring. Another way mealworms may display behavioral immunity is how they may tolerate infections by limiting negative effects on their reproductive success. For example, mealworm beetles tolerate a high number of cysticercoids of H. diminuta at the expense of their own fitness and longevity. Conversely, males produce enhanced spermatophores containing superior nuptial gifts; once transferred, these investments elevate female fecundity and fertilization success.
The NAS report described the level of lowest exposure from Greer et al. as a "no-observed-effect level" (NOEL). However, there was actually an effect at that level although not statistically significant largely due to small size of study population (four of seven subjects showed a slight decrease in iodide uptake). Reduced iodide uptake was not considered to be an adverse effect, even though it is a precursor to an adverse effect, hypothyroidism. Therefore, additional safety factors, would be necessary when extrapolating from the point of departure to the RfD. Consideration of data uncertainty was insufficient because the Greer, et al. study reflected only a 14-day exposure (=acute) to healthy adults and no additional safety factors were considered to protect sensitive subpopulations like for example, breastfeeding newborns. Although there has generally been consensus with the Greer et al. study, there has been no consensus with regard to developing a perchlorate RfD. One of the key differences results from how the point of departure is viewed (i.e., NOEL or "lowest-observed-adverse-effect level", LOAEL), or whether a benchmark dose should be used to derive the RfD. Defining the point of departure as a NOEL or LOAEL has implications when it comes to applying appropriate safety factors to the point of departure to derive the RfD. In early 2006, EPA issued a "Cleanup Guidance" and recommended a Drinking Water Equivalent Level (DWEL) for perchlorate of 24.5 μg/L.
Noboa has adopted a militarized approach to crime in Ecuador, frequently invoking states of emergency, expanding the military role in internal security, weakened judicial institutions, and raising human rights concerns. Supporters say his approach has helped to fight crime. Critics say Noboa is an autocrat, and accuse him of human rights violations, centralization of power and undermining press freedom.
Pressure sores, also called bedsores or pressure ulcers, are injuries to the skin and tissue caused by staying in one position for too long. To treat them, the skin should be washed with lukewarm water and dried completely, especially in areas where skin touches skin, like between the toes, under the breasts, in the groin, and under the arms. Harsh soaps should be avoided—it is better to use gentle, pH-balanced cleansers. Moisturizers can help protect the skin, but they shouldn't be used between the toes. It is best to apply a hypoallergenic moisturizer twice a day, especially on the arms and legs, and avoid rubbing the skin too hard.
Sources: en.wikipedia.org
=== July === 1 July – Local Government Minister Lee Rowley formally writes to South Cambridgeshire District Council to request they end their trial of a four-day working week "immediately" amid concerns about "value for money". The scheme, launched in January 2023, is scheduled to run until March 2024. Seven Just Stop Oil protestors are arrested after attempting to disrupt the 2023 London Pride celebrations by blocking the route of the parade. Five people are subsequently charged in connection with the incident. 2 July – Amanda Pritchard, the Chief Executive of NHS England, announces the launch of a further seven specialist gambling addiction clinics in England as the number of people being referred for help because of gambling addiction sees a sharp increase. 3 July – Lord Chancellor and Justice Secretary Alex Chalk asks the Parole Board to reconsider its decision to release child killer Colin Pitchfork. Ranibizumab, a drug that can prevent blindness in premature babies, is made available on the NHS in England. 4 July – Thames Water is fined £3.3m for discharging millions of litres of untreated sewage into two rivers which resulted in the death of 1,400 fish. Forest Green Rovers appoint Hannah Dingley as their caretaker manager, making her the first woman to manage a men's football team in English professional football. 5 July – Train companies in England launch a 21-day consultation over plans to closing hundreds of ticket offices. Two Just Stop Oil protestors briefly halt play at the 2023 Wimbledon Championships by invading the tennis court and throwing orange confetti.
1929: British crystallographer and activist Kathleen Lonsdale proved that the benzene ring is flat by using X-ray diffraction methods to elucidate the structure of hexamethylbenzene. She was also the first to use Fourier spectral methods while solving the structure of hexachlorobenzene in 1931.
Sherman (1930–2008), 12 US patents John Sherwood (died 2020), British physical chemist Nevil Vincent Sidgwick (1873–1952), English theoretical chemist, known for work in valency Osamu Shimomura (1928–2018), 2008 Nobel Prize in Chemistry Hideki Shirakawa (1936–2026), 2000 Nobel Prize in Chemistry Alexander Shulgin (1925–2014), pioneer researcher in Psychopharmacology and Entheogens Salimuzzaman Siddiqui (1897–1994), Pakistani chemist, pioneer in natural products chemistry Oktay Sinanoglu (1935–2015), Turkish chemist Joseph H. Simons (1897–1983), U.S. chemist, discoverer of fluorocarbons, used in gaseous diffusion of Uranium for Manhattan project Jens Christian Skou (1918–2018), 1997 Nobel Prize in Chemistry Richard Smalley (1943–2005), 1996 Nobel Prize in Chemistry Michael Smith (1932–2000), 1993 Nobel Prize in Chemistry Ascanio Sobrero (1812–1888), Italian chemist, discoverer of nitroglycerin Frederick Soddy (1877–1956), British chemist, 1921 Nobel Prize in Chemistry Susan Solomon (born 1956), American atmospheric chemist Ernest Solvay (1838–1922), Belgian chemist and industrialist S.P.L. Sørensen (1868–1939), Danish chemist Gabor A.
In chemistry, yield, also known as reaction yield or chemical yield, refers to the amount of product obtained in a chemical reaction. Yield is one of the primary factors that scientists must consider in organic and inorganic chemical synthesis processes. In chemical reaction engineering, "yield", "conversion" and "selectivity" are terms used to describe ratios of how much of a reactant was consumed (conversion), how much desired product was formed (yield) in relation to the undesired product (selectivity), represented as X, Y, and S. The term yield also plays an important role in analytical chemistry, as individual compounds are recovered in purification processes in a range from quantitative yield (100 %) to low yield (< 50 %).
=== Insurgents === Natural enemies of the Agents of the Four Seasons. They are divided into Reformists, whose goal is to threaten the Agents' safety to pressure institutions into changing the laws governing their divine powers, and Defeaters, whose goal is to eliminate the Agents out of hatred for the seasons.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.